Dana Binyamin

All Publications

• Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the gut. Nature reviews. Gastroenterology & hepatology Liu, S., Domingo-Vidal, M., Madhu, B., Binyamin, D., Thaiss, C. A., Levy, M. 2026

  Abstract

  The gastrointestinal tract harbours a vast chemical diversity of small molecules, consisting of dietary nutrients, microorganism-derived metabolites and metabolic products of the host. The latest evidence highlights a direct involvement of different metabolites in the diverse aetiologies of intestinal diseases, ranging from inflammatory to metabolic and neoplastic conditions. The accessibility of the gastrointestinal tract to oral intervention suggests that fine-tuning the levels of intestinal metabolites might be a promising and currently underutilized therapeutic strategy. Here, we provide a conceptual overview of the recurring mechanistic themes by which metabolites shape the biology of immune cells, epithelium and neurons of the gastrointestinal tract. Additionally, we classify metabolites according to possible categories of therapeutic intervention, and summarize the latest preclinical and clinical data unveiling the roles of intestinal metabolites in the pathophysiology of major diseases of the gastrointestinal tract, including inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, enteric infection, food allergy, coeliac disease, as well as obesity and metabolic syndrome. In each case, we provide an overview of the mechanisms by which intestinal metabolites have been associated with disease aetiology. In addition, we discuss possible metabolite-based strategies for intervention. Our overall goal is to provide a roadmap towards developing metabotherapies for intestinal disease.

  View details for DOI 10.1038/s41575-026-01178-9

  View details for PubMedID 41772119

  View details for PubMedCentralID 6034115

• Probiotics Ameliorate Histological Alterations and Prevent Increases in Cytokine and Toxin Levels in Mice Infected with Various <i>Clostridioides difficile</i> Strains PROBIOTICS AND ANTIMICROBIAL PROTEINS Hamo, Z., Ninio, H., Azrad, M., Binyamin, D., Zigdon, M., Roshrosh, H., Peretz, A. 2026; 18 (2): 1765-1774

  Abstract

  The severity of C. difficile infection (CDI) varies and can be influenced by bacterial strain, toxin levels, and antibiotic treatment. Current treatments are limited due to high recurrence rates and potential risks. This study aimed to characterize the manifestations of CDIs induced by various bacterial strains in mice and to assess the effects of different probiotic strains on these manifestations, with a focus on intestinal alterations, immune response, and toxin concentrations. The tested C. difficile strains induced significant intestinal damage and disrupted intestinal epithelial integrity, as indicated by reduced ZO-1 levels, with responses varying across strains. In addition, IL-6, TNF-α, and secreted toxin levels varied across the animal groups, with the highest levels seen in mice infected with sequence type 42 or 104. Administration of Lactobacillus acidophilus, Bifidobacterium bifidum, or Lactobacillus paracasei following CDI induction reduced intestinal damage, with the degree of rescue varying between probiotic strains. Lactobacillus paracasei demonstrated the most notable potential in alleviating CDI, marking its potential as an adjunct to conventional therapies for CDI.

  View details for DOI 10.1007/s12602-025-10586-3

  View details for Web of Science ID 001511356600001

  View details for PubMedID 40531412

  View details for PubMedCentralID PMC13013258